



11644 #
#14

C014CIP/DIV2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Phillip Gambel
Group : 1644
Applicants : Michael J. Yellin et al.
Application No.: 09/342,314 Confirmation No. 6376
Filed : June 29, 1999
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-
BAM (CD40-L) MONOCLONAL ANTIBODY 5C8 IN
THE TREATMENT OF ATHEROSCLEROSIS

RECEIVED
DEC 13 2001
TECH CENTER 1600/2900

New York, New York
December 4, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is a Third Supplemental
Information Disclosure Statement in the above-identified
application.

In accordance with 37 C.F.R. § 1.97, this Third
Supplemental Information Disclosure Statement is accompanied
by:

[X] a Statement as required under 37 C.F.R.
§ 1.97(e)(1) or § 1.97(e)(2);

[X] the fee as set forth in 37 C.F.R. § 1.17(p).


12/12/2001 SDUONG 00000070 09342314

01 FC:126

180.00 OP

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Third Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Margaret A. Pierri (Reg. No. 30,709)
Attorneys for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS

P.O. Box 2327
Arlington Virginia 22202

December 4, 2001

Lillian Garcia



Signature of Person Signing



#15

C014CIP/DIV2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
DEC 13 2001
TECH CENTER 1600/2900

Examiner : Phillip Gambel
Group : 1644
Applicants : Michael J. Yellin et al.
Application No.: 09/342,314 Confirmation No. 6376
Filed : June 29, 1999
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF ATHEROSCLEROSIS

New York, New York
December 4, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97,
applicants make of record the following documents, copies
of which are submitted herewith:

Other Documents

Francois Mach et al. "Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis, *Proc. Natl. Acad. Sci., USA* 94:1931-1936 (1997).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form

PTO-1449.

12/12/2001 SDUONG 00000073 09342314


01 FC:126

180.00 OP

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.


A check in payment of the \$180.00 fee, pursuant to 37 C.F.R. § 1.17(p), is transmitted herewith. Additionally, the transmittal letter accompanying this document, sent in duplicate, states that the Director is hereby authorized to charge payment of any additional fees required in connection with this Fourth Supplemental Information Disclosure Statement to Deposit Account No. 06-1075.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Margaret A. Pierri (Reg. No. 30,709)
Attorneys for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax : (212) 596-9090

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS
P.O. BOX 2327
ARLINGTON, Virginia 22202-0207
December 4, 2001
Lillian Garcia


Signature of Person Signing



C014CIP/DIV2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Phillip Gambel
Group : 1644
Applicants : Michael J. Yellin et al.
Application No.: 09/342,314 Confirmation No. 6376
Filed : June 29, 1999
For : THERAPEUTIC APPLICATIONS FOR THE
ANTI-T-BAM (CD40-L) MONOCLONAL
ANTIBODY 5C8 IN THE TREATMENT OF
ATHEROSCLEROSIS

RECEIVED
DEC 13 2001
TECH CENTER 1600/2900

New York, New York
December 4, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

Sir:

Pursuant to 37 C.F.R. § 1.97(d), applicants hereby request consideration of the Third Supplemental Information Disclosure Statement incorporated herein below. The Third Supplemental Information Disclosure Statement cites documents recently cited in a September 18, 2001 Supplementary European Search Report in applicants' corresponding European patent application.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

In the below-incorporated Third Supplemental Information Disclosure Statement, applicants state, as required by 37 C.F.R. § 1.97 (d)(1) and pursuant to 37 C.F.R. § 1.97 (e)(1), that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

A check in the amount of \$180.00, in payment of the fee as set forth in 37 C.F.R. § 1.17(p) is enclosed herewith. In the Transmittal Letter accompanying this paper, the Director is hereby authorized to charge any additional fee due, or refund any overpayment made, in connection with this Statement, to Deposit Account No. 06-1075.

Accordingly, consideration of the Third Supplemental Information Disclosure Statement is respectfully requested.

Third Supplemental Information Disclosure Statement

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), applicants make of record the following documents, copies of which are submitted herewith:

Other Documents

Fred Ramsdell et al., "CD40 Ligand Acts As a Costimulatory Signal for Neonatal Thymic Yδ T Cells", *J. Immunol.* 152:2190 (1994).

Josette Peguet-Navarro et al., "Functional Expression of CD40 Antigen on Human Epidermal Langerhans Cells", *J. Immunol.* 155:4241-4247 (1995).


Peter A. Kiener et al., "Stimulation of CD40 with Purified Soluble gp39 Induces Proinflammatory Responses in Human Monocytes", *J. Immunol.* 155:4917-4925 (1995).


For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

The documents are listed because they were cited in the September 18, 2001 Supplementary European Search Report on applicants' corresponding European patent application.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Consideration of this Third Supplemental Information
Disclosure Statement is respectfully requested.


James F. Haley, Jr (Reg. No. 27,794)
Margaret A. Pierri (Reg. No. 30,709)
Attorneys for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax : (212) 596-9090

I Hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS
P.O. Box 2327
Arlington, Virginia 22202
December 4, 2001
Lillian Garcia

Signature of Person Signing